Different types of nanoparticles were synthetized and studied either as a drug itself or as a drug delivery system aiming to combine benefits of individual particles. In this work we focused on the encapsulation of fluorescently labelled ruthenium dendrimers (FITC-CRD13) possessing anticancer properties  into the lipid vesicles composed of DMPC/DMPG/Cholesterol. FITC-CRD13 dendrimers (10 µM) were encapsulated into the liposomes by passive loading during the hydration step of lipid film (t = 1.5 h, T = 40°C) in sodium-phosphate buffer (10 mM, pH 7.4) upon the continuous shaking. Subsequently, the prepared vesicles were extruded through 400nm polycarbonate membrane and characterized by 1) absorption and fluorescence spectra of nanoparticles using size exclusion chromatography (SEC-HPLC) on a 30 nm size pore column; and 2) size measurements using dynamic light scattering (DLS). Absorbance at 220 nm and fluorescence at 495/520 nm was used for detection of liposomes and FITC-CRD13 dendrimers, respectively. Firstly, liposomes were eluted at 3.35 min. Fluorescence intensity measured along the elution profile centred at this time point was monitored for dendrimers being locked in liposomes. The coelution, thus encapsulation was less extensive because the subsequent peaks in dendrimer elution profile were observed, indicating the presence of non-entrapped material sized around 70 nm at the later retention times. Hydrodynamic diameter of purified dendrimer-liposomal sample that coeluted at 3.35 min was 210±10 nm with polydispersity index 0.1 reflecting an uniform sample with respect to the particle size. The obtained results can serve for optimization of the encapsulation protocol and as a base for further studies of the dendrimer-liposomal drug delivery platform in the cancer treatment.